Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)open access
- Authors
- Cho, Hyungwoo; Yoon, Dok Hyun; Shin, Dong-Yeop; Koh, Youngil; Yoon, Sung-Soo; Kim, Seok Jin; Do, Young Rok; Lee, Gyeong-Won; Kwak, Jae-Yong; Park, Yong; Kim, Min Kyoung; Kang, Hye Jin; Yi, Jun Ho; Yoo, Kwai Han; Lee, Won Sik; Park, Byeong Bae; Jo, Jae Cheol; Eom, Hyeon-Seok; Kim, Hyo Jung; Jeong, Seong Hyun; Won, Young-Woong; Sohn, Byeong Seok; Kwon, Ji-Hyun; Suh, Cheolwon; Kim, Won Seog
- Issue Date
- Apr-2023
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Peripheral T-cell lymphoma; Treatment pattern; Autologous stem cell transplantation
- Citation
- CANCER RESEARCH AND TREATMENT, v.55, no.2, pp.684 - 692
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 55
- Number
- 2
- Start Page
- 684
- End Page
- 692
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/189358
- DOI
- 10.4143/crt.2022.1434
- ISSN
- 1598-2998
- Abstract
- PURPOSE: We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods: Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
RESULTS: A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
CONCLUSION: The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.